Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience Abstract #2145

Introduction: Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of neoplasms associated with paraneoplastic syndromes. Venous thromboembolism (VTE) is a frequent complication in neoplastic patients and it is associated with increased morbidity and mortality. To date, there have been no specific studies in NEN, except for glucagon-secreting tumors
Aim(s): To retrospectively evaluate the incidence of VTE in GEP-NEN
Materials and methods: From 2000 to 2016 all the patients diagnosed with GEP-NEN at our Institution were retrospectively evaluated. Major thrombotic events were: deep venous thrombosis (DVT) and pulmonary embolism (PE). 162 patients (71 males, median age 64 years) were included. The site of primary tumor was the gut in 92, the pancreas in 54 and unknown in 6. Grading was G1 in 89 case, G2 in 34, G3 in 5 (not available in 4). TNM stage was I in 63 patients, II in 14, III in 20 and IV in 38
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Federica Alessandra Cavalcoli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2191 Endocrine Paraneoplastic Syndromes in Patients with Neuroendocrine Neoplasms
Introduction: Endocrine paraneoplastic syndromes (ePNS) result from production of bioactive substances from tumours not related to their expected tissue of origin. Neuroendocrine neoplasms (NENs) have been associated with ectopic secretion of several hormones, but the prevalence of ePNS has only been described in a small number of studies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Eleftherios Chatzellis
#418 Chromogranin A (CgA) in the Diagnosis and Monitoring of Patients with Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NET): A Single-Institution Experience
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NET) are heterogeneous neoplasms with different malignancy. Plasma chromogranin A (CgA) may play an important role in predicting outcome.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sara Massironi
Keywords: CgA, GEP-NET
#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#1108 Regression of Paraneoplastic Optic Neuropathy Associated with Glucagonoma After Surgical Resection
Introduction: Glucagonomas-associated ocular manifestations have been exceptionally reported.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Lucie Defour
#506 Paraneoplastic Neurological Syndrome in a Patient with a Pancreatic Well-Differentiated Endocrine Tumor
Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Maria Pia Brizzi